HEALTH PROFESSIONAL · SOURCE READING

Treatment of Recurrent or Refractory Childhood AML

Source: Childhood Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 15, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

The diagnosis of recurrent acute myeloid leukemia (AML) is made when patients who were in previous remission after therapy develop more than 5% bone marrow blasts. The diagnosis of refractory AML is made when complete remission is not achieved by the end of induction therapy.

Continue within this section

Recurrent Childhood AML →Refractory Childhood AML (Induction Failure) →Treatment Options Under Clinical Evaluation →

Preserved source evidence · Not medical advice